BioWorld Asia

Aug. 4, 2004

Zeltia Subsidiary Neuropharma Brings In EUR16M For Alzheimer's

Neuropharma SA, a subsidiary of Zeltia Group, raised €16 million in its first external funding round to progress several preclinical programs in Alzheimer's disease. (BioWorld International) Read More

Gearing Up To Crack Down On Animal Terrorism' In UK

Researchers: Genome Sequence To Hasten New Acne Therapies

EU Looking Ahead To Better Conditions For Biotech Sector

Ireland Moving To Strengthen Biomanufacturing Capabilities

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...